eli lilly trials retatrutide New Phase 3 data just dropped 👀 Lilly's trial reported average weight loss approaching 30%, with some patients achieving results historically associated with bariatric surgery. A few important caveats Why Eli Lilly's Next-Gen Obesity

Proc Natl Acad Sci U S A 107(11):52085213

Semaglutide is typically used as a long-term treatment for chronic weight management

Proper clinical oversight includes review of medical history, medication interactions, cardiovascular risk, and ongoing monitoring

Beneficial additions Some GLP-1 medications come compounded with additional ingredients that may enhance results or reduce side effects

However, many people benefit from continued fiber supplementation regardless of GLP-1 use, as most adults do not meet the recommended 25 to 35 grams of daily fiber from food alone

However, Semaglutide remains one of the most established and trusted GLP-1 medicines because of its strong long-term safety and cardiovascular research